Litigation Details for Alcon Research Ltd. v. Wockhardt Limited (D. Del. 2013)

Alcon Research Ltd. v. Wockhardt Limited (D. Del. 2013)

Docket		Date Filed	2013-12-19
Court	District Court, D. Delaware	Date Terminated	2014-11-06
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	8,268,299; 8,323,630; 8,388,941
Link to Docket	External link to docket

Details for Alcon Research Ltd. v. Wockhardt Limited (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-12-19				External link to document

Alcon Research Ltd. v. Wockhardt Limited (1:13-cv-02040): Litigation Summary, Patent Issues, and Generic Entry Risk

Last updated: July 24, 2026

Executive summary: The case Alcon Research Ltd. v. Wockhardt Limited, No. 1:13-cv-02040 (U.S. District Court, District of Delaware) is an IP dispute tied to Alcon’s ophthalmic patent estate and Wockhardt’s generic development/ANDA-related activity. The litigation framework aligns with typical Hatch-Waxman playbooks: infringement allegations anchored to Orange Book-listed patents and Wockhardt’s statutory certifications. The decision record determines (1) which asserted claims survive, (2) any injunction scope, and (3) the effective window for generic/at-risk launch.

Important: A complete, accurate litigation summary requires access to the docket filings and the case’s asserted patent claims and orders. This information is not present in the prompt, and producing it without docket-backed facts would risk inaccuracy.

What is the litigation background for Alcon Research Ltd. v. Wockhardt Limited 1:13-cv-02040?

Short answer: The matter is a federal patent infringement action in Delaware, filed by Alcon Research Ltd. against Wockhardt Limited and aimed at stopping infringement tied to a generic ophthalmic product.

Key docket elements typically determinative in Hatch-Waxman cases

• Jurisdiction and venue: Federal patent litigation in Delaware under 35 U.S.C. § 271.
• Case posture: Complaint alleging infringement of specific patents listed for the reference listed drug (RLD) in the Orange Book.
• Generic triggering event: ANDA submission and Paragraph IV (or other) patent certifications, plus discovery on notice, product development, and infringement theory.

Which patents were asserted in Alcon Research Ltd. v. Wockhardt Limited 1:13-cv-02040?

Short answer: The asserted patent set and claim-by-claim infringement bases must be extracted from the complaint, amended pleadings, and claim chart record.

What to extract from the case filings (required for a correct analysis)

• Asserted Orange Book patents (numbers, publication/application IDs, assignees).
• Claim scope: method-of-use vs composition vs formulation claims.
• Contested infringement elements: active ingredient equivalents, concentration, formulation composition, solubilization system, particle size, lens/ocular delivery features, and manufacturing controls.

What did Wockhardt argue in response in Alcon Research Ltd. v. Wockhardt Limited 1:13-cv-02040?

Short answer: Wockhardt’s defenses in this category of case typically include non-infringement, invalidity (anticipation/obviousness), and statutory/nonstatutory defenses tied to ANDA certification and notice.

Common defense themes that must be tied to docket filings

• Non-infringement: “no match” on claim limitations (e.g., formulation parameters).
• Invalidity: anticipation by prior art, obviousness, lack of written description or enablement.
• Hatch-Waxman statutory defenses: defects in notice/timing, failure to comply with prerequisites, or licensing/waiver arguments if present.

What did the court decide in Alcon Research Ltd. v. Wockhardt Limited 1:13-cv-02040?

Short answer: A litigation summary and commercial impact analysis depends on whether the court issued:

• an order on a Rule 12 motion,
• a Markman claim construction ruling,
• summary judgment on infringement/validity, and/or
• a final decision after trial or stipulated judgment.

Outcomes that materially change generic entry timing

• Dismissal of some asserted patents.
• Construction that narrows claim scope.
• Invalidity finding that eliminates asserted claims.
• Injunction scope affecting FDA approval or launch timing (and any carve-outs).

How does 1:13-cv-02040 affect generic entry and at-risk launch for the relevant Alcon ophthalmic drug?

Short answer: The litigation’s effect depends on:

• which patents survive to final judgment,
• whether an injunction issues,
• and whether FDA approval/launch can occur under 21 U.S.C. § 355(j) once the “patent hurdle” is cleared.

Generic entry scenarios that require the court’s specific results

• Scenario A: patents invalidated or not infringed for all asserted claims → launch pathway clears earlier.
• Scenario B: one or more patents upheld → launch barred until expiration or design-around.
• Scenario C: settlement licenses with specified “carve-out” dates or revenue-share terms → modified exclusivity timeline.

What are the Paragraph IV and Orange Book implications in Alcon Research Ltd. v. Wockhardt Limited 1:13-cv-02040?

Short answer: Paragraph IV outcomes determine 30-month stay status (or earlier triggers) and drive settlement leverage.

What must be confirmed from the docket

• Whether Wockhardt’s certification was Paragraph IV versus Paragraph III or Paragraph I/II.
• Whether any stay was entered, modified, or terminated by court actions.
• Whether Alcon obtained a temporary restraining order or preliminary injunction.

Does Alcon Research Ltd. v. Wockhardt Limited 1:13-cv-02040 include settlements or licensing agreements?

Short answer: Settlement terms are usually disclosed through docket entries (stipulations of dismissal, joint status reports, consent injunctions). Without the actual filings, the presence and content of any settlement cannot be stated reliably.

Settlement artifacts that matter for deal modeling

• Dismissal with prejudice tied to patent list.
• Stipulated injunction with carve-out design-around requirements.
• License with field-of-use and term controls.

How strong is Alcon’s patent estate as reflected by 1:13-cv-02040?

Short answer: Strength is assessed by outcomes on asserted claims and the court’s handling of prior art and claim construction.

Metrics that quantify “estate strength” in this case

• % of asserted claims surviving invalidity and non-infringement challenges.
• Number of patents held not invalid or found not infringed.
• Whether certain patents were dismissed early (weakness indicator) or upheld after construction (strength indicator).

How does 1:13-cv-02040 compare with other Alcon vs generic litigation?

Short answer: A proper comparison requires parallel-case outcomes in the same therapeutic class (same RLD, different ANDA filers) and the same patent families. Those must be derived from docket-linked patent numbers and RLD identification.

Regulatory and FDA pathway impact: what changes for Wockhardt in light of 1:13-cv-02040?

Short answer: The court’s enforcement posture can affect timing of FDA approval, launch, and design-around strategies.

What to tie to the litigation order

• Launch permissions subject to injunction or stay.
• Changes to manufacturing or formulation if design-around was attempted.
• Timing of any FDA “approval-to-launch” gap created by the litigation.

What generic entry risks exist for Wockhardt based on 1:13-cv-02040?

Short answer: Risk is a function of which patents remain enforceable and whether Wockhardt can design around claim limitations.

Risk drivers to extract from the docket and claim charts

• Claim coverage of formulation or method-of-use features.
• Whether the court construed key terms narrowly or broadly.
• Whether invalidity defenses were rejected on the same prior art.

---

Key Takeaways

• Case identity: Alcon Research Ltd. v. Wockhardt Limited, No. 1:13-cv-02040, is a Delaware federal patent dispute consistent with Hatch-Waxman infringement tied to an ophthalmic generic program.
• Commercial relevance: The enforceability of asserted Orange Book patents and the presence of any injunction or settlement drive generic launch timing and at-risk entry risk.
• What’s required for a complete, correct analysis: asserted patent numbers/claims, docket milestones, claim constructions, and final rulings must be taken directly from case filings to avoid factual errors.

---

FAQs

1. What does “1:13-cv-02040” indicate about where the case was filed and what type of claims were likely raised?
2. How do Paragraph IV certifications typically map to the 30-month stay in Delaware Hatch-Waxman cases like this one?
3. What claims are usually asserted in ophthalmic formulation patent cases, and what elements are typically litigated?
4. What docket events (Markman, summary judgment, injunction) most directly determine generic entry timing?
5. How do settlements in ANDA patent cases typically modify launch dates and design-around requirements?

---

References

1. U.S. District Court docket, Alcon Research Ltd. v. Wockhardt Limited, No. 1:13-cv-02040.